Seattle Genetics, Inc. and Agensys, Inc., an Affiliate of Astellas Pharma Inc., Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer

Published: Jul 20, 2010

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

Back to news